IMUNON, Inc. CEO Stacy R. Lindborg, Ph.D., issued a letter to shareholders on June 2, 2025, recapping a year of significant clinical achievements and outlining the company's strategic position. The letter highlighted the advancement of IMNN-001 into the pivotal Phase 3 OVATION 3 Study for newly diagnosed advanced ovarian cancer.
The CEO emphasized the powerful and highly encouraging results from the Phase 2 OVATION 2 Study, which demonstrated IMNN-001 as the first immunotherapy with a favorable safety profile to show survival benefits in a frontline setting. These key findings were scheduled for presentation at the 2025 ASCO Annual Meeting and simultaneous publication in Gynecologic Oncology.
Lindborg also discussed the validation of the TheraPlas platform and the company's financial discipline, including efforts to conserve cash and align critical needs with available capital. She noted the increasing interest from institutional investors and the company's position to potentially meet the $1 NASDAQ listing requirement in the near term, underscoring a bright future for IMUNON.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.